Vertex Pharmaceuticals | VRTX - Sales Revenues

Stock Price
426.01
Daily Change
-4.28 -0.99%
Monthly
-3.87%
Yearly
-14.20%
Q2 Forecast
421.08

Vertex Pharmaceuticals reported $3.19B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
J&J USD 24.1B 500M Mar/2026
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025